# US 2012/0252744 A1 · Pharmaceutical Composition and Method for Neoangiogenesis/Revascularization Useful in Treating Ischemic Heart Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252744 A1
- Document ID: US20120252744A1
- Status: Published application
- Kind: A1
- Application number: 13/517,600
- Filed: 2012-06-14
- Published: 2012-10-04
- Earliest claimed: 2005-10-27
- Assignees: Lead Billion Limited
- Inventors: Ming Li; Lei Cheng; Hong Wei Liu
- Web page: https://patentgrep.com/patent/US20120252744A1

## CPC

- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition and a method of treating ischemic heart diseases by growing new blood vessels that supply oxygen and nutrients to infarcted heart tissues throughout the entire infarct zone and for preventing cardiomyocyte apoptosis in ischemic events. The pharmaceutical composition contains an active ingredient compound with a backbone structure of formula (I).

## Claims

### Claim 1

A method of treating an ischemic disease in a mammalian subject, comprising a step of administering to said mammalian subject an effective amount of a compound with a backbone structure showing in formula (I) or a functional derivative of said compound.

### Claim 2 (depends on 1)

The method of claim 1, wherein said compound or functional derivative exerts a therapeutic effect by revascularization in an ischemic or infracted heart tissue of said mammalian subject.

### Claim 3 (depends on 2)

The method of a claim 2, where said revascularization occurs within 24 to 72 hours following a treatment with said compound or functional derivative.

### Claim 4 (depends on 1)

The method of claim 1, wherein said ischemic disease is ischemic heart diseases or limb ischemia.

### Claim 5 (depends on 1)

The method of claim 1, wherein said ischemic disease is caused by atherosclerosis of coronary arteries.

### Claim 6

A method for revascularization in ischemic or infracted myocardia of a mammalian subject, comprising a step of treating said ischemic or infracted myocardia with a compound with a backbone structure showing in formula (I) or a functional derivative of said compound.

### Claim 7 (depends on 6)

The method of claim 6, wherein said compound or functional derivative of said compound up-regulates expressions of VEGF and bFGF.

### Claim 8 (depends on 6)

The method of claim 6, wherein said compound or functional derivative of said compound is injected directly into tissues in said ischemic or infracted myocardia.

### Claim 9 (depends on 6)

The method of claim 6, wherein said compound or functional derivative of said compound is delivered to tissues in said ischemic or infracted myocardia via oral administration.

### Claim 10 (depends on 6)

The method of claim 6, wherein said compound or functional derivative of said compound is delivered to tissues hi said infarcted myocardia via subcutaneous injection, intramuscular injection, or intravenous infusion.

### Claim 11 (depends on 1)

The method of claim 1, wherein at least 95% by weight of said composition is identified compounds.

### Claim 12 (depends on 1)

The method of claim 1, wherein said compound is said backbone structure itself without any substitution.

### Claim 13 (depends on 1)

The method of claim 1, further comprising adding a piece of information on usefulness of said compound, wherein said information indicates that said compound is beneficial to a human suffering or having suffered an ischemic heart disease.

### Claim 14 (depends on 1)

The method of claim 1, further comprising the steps of (a) formulating said compound or said functional derivative into a dosage form and (b) systematically administering said compound or said functional derivative in said dosage form to said mammalian subject.

### Claim 15 (depends on 14)

The method of claim 14, wherein said dosage form is selected from the group consisting of tablet, capsule, injection solution, syrup, suspension and powder.

### Claim 16 (depends on 6)

The method of claim 6, wherein at least 95% by weight of said composition is identified compounds.

### Claim 17 (depends on 6)

The method of claim 6, wherein said compound is said backbone structure itself without any substitution.

### Claim 18 (depends on 6)

The method of claim 6, further comprising adding a piece of information on usefulness of said compound, wherein said information indicates that said compound is beneficial to a human suffering or having suffered an ischemic heart disease.
